Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Contemporary public health and care policies expect that promoting self-reliance can help older adults prevent or recover from morbidity, including psychiatric disorders. We sought to clarify the role of self-reliance dynamics in developing and recovering from psychiatric symptoms throughout the aging process.
Method: We used dynamic time warping to analyze the temporal ordering of within-person changes in five self-reliance indicators (three self-efficacy dimensions, mastery, self-esteem) and psychiatric symptoms in = 1968 participants aged 55+ in the Longitudinal Aging Study Amsterdam, measured up to ten times across up to 30 years. Participants were categorized as symptomatic or asymptomatic based on reporting clinically relevant depressive and/or anxiety symptoms.
Results: At baseline, mean age was 63.7 years and 54.2% of participants were female. In the symptomatic group, changes in symptoms generally preceded changes in self-reliance. The reverse was observed in the asymptomatic group. Among participants with anxiety, changes in mastery preceded changes in symptoms.
Conclusion: Within-person changes in self-reliance may have limited value as early warning signs for declining mental health, although in older adults who develop anxiety, declining mastery may signal worsening symptoms. Findings underscore the complex interplay of self-reliance and psychiatric symptoms and highlight the complementary value of dynamic time warping analyses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13607863.2025.2514066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies.
Adv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Impact of Intersecting Identities on Student Well-being.
J Dev Behav Pediatr
September 2025
Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston University, Boston, MA.
John is a 12-year-old African-American boy with a Specific Learning Disorder in Reading and Generalized Anxiety Disorder who you are seeing in follow-up at your clinic. Last fall, when John was having an escalation of his anxiety symptoms at school, he enacted the behavior intervention plan (BIP) that had been previously established by his educational team of informing his teacher that he needed to leave the classroom. He then paced the hallway outside of his classroom as a method of coping with the anxiety that he was experiencing.
View Article and Find Full Text PDFEffectiveness of Enhanced Developmental Screening at 18 Months to Identify Developmental Delays.
J Dev Behav Pediatr
September 2025
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Objective: We sought to measure whether receipt of an enhanced 18-month well-baby visit with use of a developmental screening tool versus a routine 18-month well-baby visit (which typically involves developmental surveillance without screening) is associated with time to identification of developmental delays.
Method: We conducted a cohort study of children (17-22 months) in Ontario who received an 18-month well-baby visit (March 2020‒March 2022), followed to September 2022 using linked health administrative datasets. Visits were categorized as enhanced (n = 83,554) or routine (n = 15,723).
UBA5-epileptic encephalopathy: new patient, a novel variant, and a review of epileptic phenotypes.
Epileptic Disord
September 2025
Unit of Child Neurology and Psychiatry, ASST-Spedali Civili of Brescia, Brescia, Italy.
Protein ufymilation is a post-translational modification implicated in the regulation of several cellular processes. Biallelic variants in UBA5 causing a functional alteration of its protein product have been associated with early-onset epileptic encephalopathy 44 (EIEE44), a rare disease for which 28 patients have been described in the literature at present. We here report on the clinical and detailed EEG phenotype of a novel patient affected by EIEE44.
View Article and Find Full Text PDF